Stage IV ALK-Positive Lung Cancer Patient Passes Nine Years on Targeted Pills Alone
Start here
Dr. Sydney Barned, speaking at an AACR talk, described living more than nine years with stage IV ALK-rearranged lung cancer controlled entirely by oral targeted therapy. Initially misdiagnosed as pneumonia and then as stage I disease, PET imaging later showed pleural involvement. A first-generation ALK inhibitor kept her stable for 5.5 years. In 2022, after oligoprogression with 3 brain metastases, she switched to a second-generation inhibitor, which resolved the lesions; she has remained stable for nearly 4 years since. Over the entire course she has received no chemotherapy, radiotherapy or surgery, and she credits research funding with directly extending patients' functional survival.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- youtube.comDr. Sydney Barned at AACR: Nine-Plus Years Living With Stage IV ALK-Positive Lung Cancer on Targeted Pills Alone
Dr. Sydney Barned described her stage IV ALK-rearranged lung cancer journey at an AACR talk, after initial misdiagnosis as pneumonia or stage I disease and PET evidence of pleural involvement. A first-generation ALK inhibitor kept her stable for 5.5 years; after oligoprogression in 2022 with 3 brain metastases, switching to a second-generation inhibitor resolved the lesions and she has remained stable for nearly 4 years. Over nine years she has used oral targeted therapy alone, with no chemotherapy, radiotherapy or surgery, and she credits research funding with directly extending patients' functional survival.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 18 04:00)·Change over 24h in the comparable set –
The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's heat; the left and right arrow keys work too.